MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
CAS No. : 2168525-92-4
MCE 国际站:UT-34
产品活性:UT-34 是一种有效的,选择性的,具有口服活性的第二代泛雄激素受体 (AR) 拮抗剂和降解剂,对野生型 AR,F876L-AR 和 W741L-AR 的 IC50 分别为 211.7 nM,262.4 nM 和 215.7 nM。UT-34 与配体结合结构域 (LBD) 和功能 1 (AF-1) 结构域结合,并需要泛素蛋白酶体途径来降解 AR。UT-34 具有抗前列腺癌的功效。
研究领域:Vitamin D Related/Nuclear Receptor
作用靶点:Androgen Receptor
In Vitro: UT-34 (3-10 µM; 24 hours; LNCaP cells) treatment inhibits the expression of PSA and FKBP5 and growth of LNCaP cells starting from 100 nM with maximum effect observed at 10 μM.
UT-34 (0.1-10 µM; 24 hours; LNCaP cells) treatment results in a reduction of AR levels at 1000 nM in LNCaP cells.
Treatment of ZR-75-1 cells maintained in serum-containing growth medium with UT-34 results in downregulation of AR protein levels, but not estrogen receptor (ER) or progesterone receptor (PR) levels. Furthermore, in MDA-MB-453 breast cancer cells that express AR and glucocorticoid receptor (GR), UT-34 induces the downregulation of AR, but not GR.
UT-34 is an effective degrader of both AR and AR-V7. LNCaP-ARV7 cells are treated for 24 hours in the presence of 0.1 nM R1881 or 10 ng/mL Doxycycline. Doxycycline induces the expression of EDN2, which is inhibited by UT-34, while UT-34 inhibits the expression of R1881-induced FKBP5 gene expression.
In Vivo: UT-34 (20-40 mg/kg; oral administration; daily; for 14 days; NSG mice) at 20 and 40 mg/kg reduces the seminal vesicle weight by 10%-20% and 50%-60 %, respectively.
UT-34 inhibits androgen-dependent tissues such as prostate and seminal vesicles in rats, and the growth of Enzalutamide-resistant castration-resistant prostate cancer (CRPC) xenografts. UT-34 also induces tumor regression in intact immunocompromised rats.
相关产品:Bioactive Compound Library Plus | Anti-Cancer Compound Library | Endocrinology Compound Library | Anti-Breast Cancer Compound Library | Transcription Factor-Targeted Library | Anti-Prostate Cancer Compound Library | Nuclear Receptor Compound Library | Heterocyclic Compound Library | Highly Selective Inhibitors Library | Medroxyprogesterone acetate-d3 | Androgen receptor antagonist 4 | VPC-13789 | Acetyl-ACTH (7-24) (human, bovine, rat) | CSRM617 hydrochloride | Ar-V7-IN-1 | Acetyl-ACTH (3-24) (human, bovine, rat) | Cyproterone acetate-d3 | TD-802 | GTx-007 | RD162 | MK-4541 | S-23 | MI-136 | MK-3984 | Boc-Glycine-2-13C | SK33 | Brassicasterol | Medroxyprogesterone acetate | Apalutamide-d3 | Cyprodinil | Linuron | ARV-766 | DHEA | CLP-3094 | AR antagonist 2 | Prochloraz | D4-abiraterone | Spironolactone-d3-1
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物 | 寡核苷酸 | 抗体 | 点击化学
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
品牌介绍:
• MCE (MedChemExpress) 拥有200 多种全球独家化合物库,我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物;
• 50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领;
• 产品种类涵盖各种重组蛋白,多肽,常用试剂盒 ,更有 PROTAC、ADC 等特色产品,广泛应用于新药研发、生命科学等科研项目;
• 提供虚拟筛选,离子通道筛选,代谢组学分析检测分析,药物筛选等专业技术服务;
• 设有专业的实验中心和严格的质控、验证体系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
• 产品的生物活性多经各国客户实验验证;
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果;
• 专业团队跟踪最新的制药及生命科学研究进展,为您提供全球最新的活性化合物;
• 与世界各大制药公司及知名科研机构建立了长期的合作。